Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Oxacillin Sodium

FDA-approved product (capsule, oral), marketed as Bactocill, Bactocill In Plastic Container, Oxacillin Sodium and 1 more.

Registered studies
50+
Lab records
22
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Oxacillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF04

Repurposing investigation

Oxacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA9.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 9 of 22 lab records
Open Oxacillin Sodium in ChEMBL Registered studies below
Show the 22 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Oxacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

    NCT07148960 · start 2025-09-15

    Registered record
    Registry ID
    NCT07148960
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Early Dual IV Antibiotic Therapy - MRSA; Early Dual IV Antibiotic Therapy - MSSA; Single Agent IV Antibiotic Therapy - MRSA; Single Agent IV Antibiotic Therapy - MSSA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Enrolling by invitation
    Start
    2025-09-15
    Completion
    2027-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionEarly Dual IV Antibiotic Therapy - MRSA; Early Dual IV Antibiotic Therapy - MSSA; Single Agent IV Antibiotic Therapy - MRSA; Single Agent IV Antibiotic Therapy - MSSA
    PhasePhase 4
    Registry statusEnrolling by invitation

  • Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia

    NCT06726395 · start 2025-03-10

    Registered record
    Registry ID
    NCT06726395
    Conditions
    Staphylococcus Aureus Bacteraemia; Staphylococcal Bacteraemia; Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia); Staphylococcus (S.) Aureus Infection
    Interventions
    Penicillin G_1200mg; cloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-03-10
    Completion
    2028-07
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteraemia; Staphylococcal Bacteraemia; Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia) +1 more
    InterventionPenicillin G_1200mg; cloxacillin
    PhasePhase 4
    Registry statusRecruiting

  • Amnioinfusion for Fetal Renal Failure

    NCT06728228 · start 2024-12-05

    Registered record
    Registry ID
    NCT06728228
    Conditions
    Multicystic Dysplastic Kidney; Polycystic Kidney Disease; Fetal Renal Anomaly; Anhydramnios; Potter Syndrome; Lung Hypoplasia; Multicystic Renal Dysplasia, Bilateral; Lower Urinary Tract Obstructive Syndrome; Bilateral Renal Agenesis
    Interventions
    Amnioinfusion
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-12-05
    Completion
    2026-11-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulticystic Dysplastic Kidney; Polycystic Kidney Disease; Fetal Renal Anomaly; Anhydramnios +5 more
    InterventionAmnioinfusion
    PhaseNot applicable
    Registry statusRecruiting

  • Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia

    NCT06336824 · start 2024-06-28

    Registered record
    Registry ID
    NCT06336824
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-06-28
    Completion
    2025-06
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionTab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    PhasePhase 3
    Registry statusUnknown

  • Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens

    NCT06616168 · start 2023-09-01

    Registered record
    Registry ID
    NCT06616168
    Conditions
    Bacterial Vaginosis
    Interventions
    Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest); Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin); Suppositoria for vaginal microflora recovery (Giynoflor); Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2023-09-01
    Completion
    2027-08-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Vaginosis
    InterventionMicrobiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest); Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin); Suppositoria for vaginal microflora recovery (Giynoflor); Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)
    PhasePhase 1
    Registry statusActive not recruiting

  • Comparing Oral Versus Parenteral Antimicrobial Therapy

    NCT05977868 · start 2023-08-04

    Registered record
    Registry ID
    NCT05977868
    Conditions
    Endovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection; Gastrointestinal Infection; Genitourinary Infection
    Interventions
    Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-08-04
    Completion
    2025-02-14
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection +2 more
    InterventionAmoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    PhasePhase 4
    Registry statusTerminated

  • Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia

    NCT06495697 · start 2023-07-19

    Registered record
    Registry ID
    NCT06495697
    Conditions
    Staphylococcus Aureus Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-07-19
    Completion
    2024-07-19
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections

    NCT05929599 · start 2023-07-05

    Registered record
    Registry ID
    NCT05929599
    Conditions
    Acute Respiratory Tract Infections; Pneumonia; Respiratory Syncytial Virus (RSV)
    Interventions
    0.9% NaCl physiological saline; LiveSpo Navax
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2023-07-05
    Completion
    2025-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Tract Infections; Pneumonia; Respiratory Syncytial Virus (RSV)
    Intervention0.9% NaCl physiological saline; LiveSpo Navax
    PhaseNot applicable
    Registry statusActive not recruiting

  • Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis

    NCT05578482 · start 2022-10-24

    Registered record
    Registry ID
    NCT05578482
    Conditions
    Atopic Dermatitis; Atopic Dermatitis Eczema; Atopic Dermatitis Flare
    Interventions
    Dicloxacillin Oral Capsule; Elocon 0.1 % Topical Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-10-24
    Completion
    2023-05
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis; Atopic Dermatitis Eczema; Atopic Dermatitis Flare
    InterventionDicloxacillin Oral Capsule; Elocon 0.1 % Topical Cream
    PhasePhase 4
    Registry statusUnknown

  • Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

    NCT05398679 · start 2022-08-17

    Registered record
    Registry ID
    NCT05398679
    Conditions
    Endocarditis Infective
    Interventions
    Cefaclor; Ciprofloxacin Tablets; Ciprofloxacin Injection; Clindamycin Oral Capsule; Clindamycin Injection; Dicloxacillin Oral Capsule; Dicloxacillin; Fusidic Acid Only Product in Oral Dose Form; Fusidic Acid Only Product in Parenteral Dose Form; Levofloxacin Oral Tablet; Levofloxacin Injection; Linezolid Oral Tablet; Linezolid Injectable Product; Moxifloxacin tablet; Moxifloxacin Injectable Product; Rifampicin Only Product in Oral Dose Form; Rifampicin Only Product in Parenteral Dose Form; Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]; Sulfamethoxazole / Trimethoprim Injectable Product; Tedizolid Oral Tablet; Tedizolid Injection; Amoxicillin Capsules; Amoxicillin; Cefaclor Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-08-17
    Completion
    2027-12-30
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocarditis Infective
    InterventionCefaclor; Ciprofloxacin Tablets; Ciprofloxacin Injection; Clindamycin Oral Capsule +20 more
    PhasePhase 4
    Registry statusRecruiting

  • Ice Application for Oxacillin-Related Phlebitis and Pain

    NCT07820956 · start 2022-04-07

    Registered record
    Registry ID
    NCT07820956
    Conditions
    Peripheral Intravenous Phlebitis; Injection Site Pain; Pain
    Interventions
    Ice Application; Room-Temperature Water-Bag Application
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-04-07
    Completion
    2022-12-31
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Intravenous Phlebitis; Injection Site Pain; Pain
    InterventionIce Application; Room-Temperature Water-Bag Application
    PhaseNot applicable
    Registry statusCompleted

  • Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

    NCT05156437 · start 2022-03-16

    Registered record
    Registry ID
    NCT05156437
    Conditions
    Endocarditis
    Interventions
    Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin; Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2022-03-16
    Completion
    2024-10-31
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocarditis
    InterventionAmoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin; Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
    PhasePhase 4
    Registry statusTerminated

  • The Effect of Dicloxacillin on Oral Absorption of Drugs

    NCT05073627 · start 2022-02-07

    Registered record
    Registry ID
    NCT05073627
    Conditions
    Healthy Volunteers; Drug-drug Interaction
    Interventions
    Dicloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-02-07
    Completion
    2022-06-22
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers; Drug-drug Interaction
    InterventionDicloxacillin
    PhasePhase 1
    Registry statusCompleted

  • DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

    NCT04775953 · start 2021-04-22

    Registered record
    Registry ID
    NCT04775953
    Conditions
    Staphylococcal Bacteraemia
    Interventions
    Cefazolin; Dalbavancin; Daptomycin; Nafcillin; Oxacillin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-04-22
    Completion
    2023-12-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Bacteraemia
    InterventionCefazolin; Dalbavancin; Daptomycin; Nafcillin +2 more
    PhasePhase 2
    Registry statusCompleted

  • Gentamicin in Cardiac Surgery

    NCT06454643 · start 2020-01-01

    Registered record
    Registry ID
    NCT06454643
    Conditions
    Cardiac Infection
    Interventions
    Flucloxacillin and gentamicin; Flucloxacillin and ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2021-01-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Infection
    InterventionFlucloxacillin and gentamicin; Flucloxacillin and ceftriaxone
    PhaseNot applicable
    Registry statusCompleted